CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.6 USD | +1.53% |
|
-2.78% | -44.49% |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 5.56M | Capitalization | 599M |
|---|---|---|---|---|---|
| Net income 2024 * | -92M | Net income 2025 * | -109M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 258M | Net cash position 2025 * | 181M | EV / Sales 2025 * | 75.2 x |
| P/E ratio 2024 * |
-6.66
x | P/E ratio 2025 * |
-5.97
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cabaletta Bio, Inc.
More recommendations
More press releases
| 1 day | +1.53% | ||
| 1 week | -2.78% | ||
| Current month | +18.37% | ||
| 1 month | -25.09% | ||
| 3 months | -38.78% | ||
| 6 months | -14.58% | ||
| Current year | -44.49% |
1 week
9.75
13.10
1 month
9.7519.04
Current year
9.7526.35
1 year
9.0226.35
3 years
0.5926.35
5 years
0.5926.35
10 years
0.5926.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 17-03-31 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 18-12-31 |
| Compliance Officer | - | 19-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 19-02-18 | |
| Chief Executive Officer | 62 | 17-03-31 | |
Mark Simon
BRD | Director/Board Member | 62 | 18-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 12.6 | +1.53% | 1,802,738 |
| 24-05-01 | 12.41 | +16.58% | 2,809,408 |
| 24-04-30 | 10.64 | +1.57% | 1,934,233 |
| 24-04-29 | 10.48 | -4.81% | 5,070,633 |
| 24-04-26 | 11.01 | -9.61% | 2,916,621 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.6
USD
Average target price
34.5
USD
Spread / Average Target
+173.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.49% | 599M | |
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
- Stock Market
- Equities
- CABA Stock
